ATTENTION:
BEFORE YOU READ THE ABSTRACT OR CHAPTER ONE OF THE PROJECT TOPIC BELOW, PLEASE READ THE INFORMATION BELOW.THANK YOU!
INFORMATION:
YOU CAN GET THE COMPLETE PROJECT OF THE TOPIC BELOW. THE FULL PROJECT COSTS N5,000 ONLY. THE FULL INFORMATION ON HOW TO PAY AND GET THE COMPLETE PROJECT IS AT THE BOTTOM OF THIS PAGE. OR YOU CAN CALL: 08068231953, 08168759420
WHATSAPP US ON 08137701720
EVALUATION OF A LOCAL ELECTROSHOCK MODEL FOR SCREENING POTENTIAL ANTI-EPILEPTIC DRUGS
CHAPTER ONE
INTRODUCTION
- Background of the study
In spite of the currently available therapeutic arsenal of old and new antiepileptic drugs (AEDs), almost one-third of epileptic patients continue to present seizures that appear to be refractory to all pharmacological schemes (1, 2). Subsequently, there is a substantial need to develop new and more effective AEDs, and numerous compounds are now in preclinical and clinical trials (2, 3).
The choice of appropriate animal models for the initial in vivo testing of a potential anticonvulsant drug is one of the most important steps in the successful search for new AEDs. At present, preclinical animal studies are indispensable in exploring the efficacy and safety of an investigational AED before its introduction in human volunteers (4-7).
Although modern cellular neurophysiological and biochemical approaches have made it possible to identify molecular targets of AEDs, in vitro testing is not likely to replace screening in animal models: on the one hand, in vitro systems cannot model the specific pharmacodynamic actions required for seizure protection since they do not assess the multidimensional parameter space, which includes not only the target molecules but also critical biomolecules that could cause side effects or interfere with the desired activity; on the other hand, in vitro testing does not assess bioavailability, brain accessibility and local delivery to the target. Therefore, only animal test systems can select compounds that are inherently anticonvulsant and are able to access the relevant brain targets (8).
If the purpose of the research is not to study the epileptic phenomenon itself but to screen new AEDs, the animal models fall into two main categories: models of acute seizures (nonepileptic animals induced to have a seizure by an electrical or chemical stimulus) and models of chronic epilepsy (animals induced to have enhanced seizure susceptibility or spontaneous seizures) (8). For practical reasons, experimental research on new AEDs has mostly been carried out on normal mice and rats in which seizures were induced by chemical or electrical means (6, 7). Indeed, with respect to screening purposes, electrically or chemically induced seizures have advantages over most genetic models since seizure-susceptible animal species may lead to an exaggeration of the anticonvulsant potency of a new drug.
1.2 Statement of the problem
Over the years, the maximal electroshock seizure (MES) model has remained one of the gold standards in early stages of testing.
Continuous search for new models closer to the human epilepsy phenomenon, the MES model will persist as the most useful tool at least at the anticonvulsant compound identification stage. Hence, we intend to describe in a single paper all the useful yet dispersed information on performing anticonvulsant screening by MES tests, drawing particular attention to experimental procedures and factors affecting the accuracy of experimental data.
- Objectives of the study
- To understand the impact of electroshock model on screening anti-epileptic drugs
- To understand the relationship between electroshock model and screening potential of anti-epileptic drugs
- Research Questions
- What is the impact of electroshock model on screening anti-epileptic drugs
- What is the relationship between electroshock model and screening potential of anti-epileptic drugs
- Research Hypothesis
H0: There is no relationship between electroshock model and screening potential of anti-epileptic drugs
H1: There is a relationship between electroshock model and screening potential of anti-epileptic drugs
HOW TO RECEIVE PROJECT MATERIAL(S)
After paying the appropriate amount (#5,000) into our bank Account below, send the following information to
08068231953 or 08168759420
(1) Your project topics
(2) Email Address
(3) Payment Name
(4) Teller Number
We will send your material(s) after we receive bank alert
BANK ACCOUNTS
Account Name: AMUTAH DANIEL CHUKWUDI
Account Number: 0046579864
Bank: GTBank.
OR
Account Name: AMUTAH DANIEL CHUKWUDI
Account Number: 3139283609
Bank: FIRST BANK
FOR MORE INFORMATION, CALL:
08068231953 or 08168759420